JPRN-UMIN000006892
Recruiting
未知
Safety and feasibility of coadministration of erlotinib and Theracurmin (nanoparticle curcumin) in patients with advanced or recurrent non-small-cell lung cancer - Safety and feasibility of coadministration of erlotinib and Theracurmin (nanoparticle curcumin) in patients with advanced or recurrent non-small-cell lung cancer
School of Medicine, Keio University0 sites12 target enrollmentStarted: December 21, 2011Last updated:
Overview
- Phase
- 未知
- Status
- Recruiting
- Enrollment
- 12
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)idiopathic pulmonary fibrosis, interstitial pneumonia, radiation pneumonitis, drug related pneumonitis 2\)plueral, peritoneal, or pericardial effusion requiring drainage 3\)active infection 4\)unable to take oral medication 5\)symptomatic eye disorders 6\)pregnant or lactating 7\)symptomatic brain metastasis 8\)other malignancies 9\)uncontrolled diabetes 10\) active complications 11\)patients whom physicians judged to be unsuitable for enrollment for other reasons
Investigators
Similar Trials
Completed
Phase 1
Safety evaluation of coadministration of erlotinib and theracurmin in non-small cell lung cancer patientsnon-small cell lung cancerJPRN-UMIN000013424Saitama Medical Center6
Active, not recruiting
Not Applicable
Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children - Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy ChildreRotaTeq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1 (e.g., G9).MedDRA version: 10Level: LLTClassification code 10017913EUCTR2005-003508-12-DEMerck and Co., Inc.522
Active, not recruiting
Not Applicable
Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children - Concomitant Use of RotaTeq™ and HEXAVAC® in Healthy ChildreEUCTR2005-003508-12-ATMerck Sharp & Dohme GesmbH
Active, not recruiting
Not Applicable
Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Infants. - Concomitant Use of RotaTeq™ and HEXAVAC® in Healthy ChildreRotaTeq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1 (e.g., G9).MedDRA version: 10Level: LLTClassification code 10017913EUCTR2005-003508-12-BEMerck Sharp & Dohme BV522
Not yet recruiting
Phase 2
To check safety and efficacy of Naltrexone in advanced esophageal cancer.Health Condition 1: C159- Malignant neoplasm of esophagus, unspecifiedCTRI/2020/03/023846Tata Memorial Hospital